Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Inc. is trading at $39.41, up 3.03% on the session. The 50 day average sits at $30.00 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 75.6, which reads as overbought, and MACD is bullish crossover. Volume is average.

The nearest support is around $27.42 with resistance near $39.99, so that band frames the current range. Average daily movement is roughly $2.40, or about 6.1% of the share price, which is what any stop placement has to allow for. The overall health score of 63 out of 100 combines a trend score of 75, momentum of 78 and a risk score of 22.

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.